A protein-based Covid-19 vaccine by Akston Biosciences that can be stored at room temperature and efficiently manufactured using existing technology was well-tolerated and provoked an immune response in all those receiving higher doses, according to data from an early-stage clinical trial, as the company vies to expand vaccine access around the world.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,